Nephro Care IPO Makes Bumper Debut on NSE SME; Lists at 90% Premium

Nephro Care India made an impressive debut on the NSE SME, listing its shares at Rs 171, which is a 90% premium over its issue price of Rs 90. The shares further climbed to Rs 179.55, reaching a 5% upper circuit and trading nearly 100% higher than the issue price.

The IPO aimed to raise Rs 41.26 crores through the fresh issue of approximately 4.58 million shares. The price band was set at Rs 85 to Rs 90 per share, with a minimum investment lot size of 1600 shares, totaling Rs 1,44,000 for retail investors.

Nephro Care allotted 825,600 shares (18.01%) to Qualified Institutional Buyers (QIBs), 619,200 shares (13.51%) to Non-Institutional Investors (NIIs), 1,444,800 shares (31.52%) to Retail Individual Investors (RIIs), and 1,238,400 shares (27.02%) to Anchor Investors. The IPO was massively oversubscribed by 715.78 times, with the retail category subscribing 634.12 times, QIB 245.14 times, and NII 1,787.19 times.

Corporate Capitalventures Pvt Ltd was the book running lead manager, Bigshare Services Pvt Ltd acted as the registrar, and Ss Corporate Securities was the market maker for the IPO.

Established in 2014 and based in Kolkata, Nephro Care India Limited specializes in providing comprehensive clinical and lifestyle solutions for patients with renal insufficiency.

The facility is staffed by expert doctors, visiting consultants, and skilled paramedical professionals. Nephro Care currently serves about 900 Chronic Kidney Disease patients monthly with a team of 5 permanent doctors and 70 paramedical staff.

Read more :

No related blogs available.